Obinutuzumab in hematologic malignancies: Lessons learned to date.

Tim Illidge, Christian Klein, Laurie H Sehn, Andrew Davies, Gilles Salles, Guillaume Cartron

    Research output: Contribution to journalArticlepeer-review


    The routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the clinical success achieved with rituximab, relapses are still common with further improvements in anti-CD20 mAb efficacy required. Many novel anti-CD20 antibodies are in development, but obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing. Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death. In preclinical models, obinutuzumab induced superior tumor remission compared with rituximab at the equivalent dose levels, and was active in rituximab-refractory tumors. Obinutuzumab exhibits encouraging efficacy as monotherapy in NHL, and combined with chemotherapy in relapsed/refractory NHL and treatment-naïve symptomatic CLL. In a recent randomized, phase III trial in patients with untreated comorbid CLL, overall response rate was significantly greater (78% vs. 65%, P
    Original languageEnglish
    JournalCancer Treatment Reviews
    Issue number9
    Publication statusPublished - Nov 2015


    • CD20
    • CLL
    • NHL
    • Obinutuzumab
    • Rituximab
    • Type II antibody


    Dive into the research topics of 'Obinutuzumab in hematologic malignancies: Lessons learned to date.'. Together they form a unique fingerprint.

    Cite this